Development of a RSK Inhibitor as a Novel Therapy for Triple Negative Breast Cancer

Metastatic breast cancer is an incurable disease and identification of novel therapeutic opportunities is vital. Triple negative breast cancer (TNBC) frequently metastasizes and high levels of activated RSK, a downstream MEK-ERK1/2 effector, are found in TNBC. We demonstrate using direct pharmacolog...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Mol Cancer Ther
Main Authors: Ludwik, Katarzyna A., Campbell, James P., Li, Mingzong, Li, Yu, Sandusky, Zachary M., Pasic, Lejla, Sowder, Miranda E., Brenin, David R., Pietenpol, Jennifer A., O’Doherty, George A., Lannigan, Deborah A.
Formato: Artigo
Idioma:Inglês
Publicado em: 2016
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5807013/
https://ncbi.nlm.nih.gov/pubmed/27528706
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1535-7163.MCT-16-0106
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados